Home › Companies › MOONLAKE IMMUNOTHERAPEUTICS › 2024-2025

MOONLAKE IMMUNOTHERAPEUTICS 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed 2025-06-06 (Item 5.07 on EDGAR). Page generated 04 October 2026.

5Ballot items
134Asset managers
707Fund votes
2025-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MOONLAKE IMMUNOTHERAPEUTICS in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by MOONLAKE IMMUNOTHERAPEUTICS

These tallies are MOONLAKE IMMUNOTHERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MOONLAKE IMMUNOTHERAPEUTICS — official shareholder meeting results, meeting held 2025-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: ● Dr. Jorge Santos da Silva	53,083,965	--	--	499,130	5,738,408	Majority: yes
Elect Director: ● Simon Sturge	52,034,156	--	--	1,548,939	5,738,408	Majority: yes
Elect Director: ● Dr. Andrew Phillips	53,338,613	--	--	244,482	5,738,408	Majority: yes
Proposal 2: Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor	59,310,209	2,856	8,438	--	0	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation	53,464,199	109,913	8,983	--	5,738,408	Majority: yes

Source: MOONLAKE IMMUNOTHERAPEUTICS, Form 8-K, filed with the SEC on 2025-06-06 — read the filing on EDGAR.

How asset managers voted at the MOONLAKE IMMUNOTHERAPEUTICS 2024-2025 meeting

Each item below shows how the 134 asset managers that disclosed a MOONLAKE IMMUNOTHERAPEUTICS vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 53,464,199AGAINST: 109,913

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 53,464,199 for, 109,913 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 73% for, 0.2% against (73% of the company cast a for/against vote).

The 132 asset managers below cast 99.8% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99.8%

FOR: 99.8%AGAINST: 0.2%ABSTAIN: 0.0%

Largest asset managers voting on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset manager	For	Vote
BVF INC/IL	19,751,284	For
Fidelity	10,185,587	For
Cormorant Asset Management, LP	7,514,392	For
T. Rowe Price	5,097,423	For
Federated Hermes	2,460,963	For
Citadel	1,409,055	For
WESTFIELD CAPITAL MANAGEMENT CO LP	1,280,597	For
AllianceBernstein	1,230,231	For
Avoro Capital Advisors LLC	1,172,060	For
HARBOR FUNDS	704,819	For
FRED ALGER MANAGEMENT, LLC	635,300	For
Logos Global Management LP	550,000	For
ALGER FUNDS	533,756	For
MARSHALL WACE, LLP	530,964	For
Camber Capital Management LP	441,000	For
Victory Capital	398,628	For
Voya	393,982	For
Putnam	383,000	For
Hood River Capital Management LLC	368,438	For
PICTET ASSET MANAGEMENT SA	291,327	For
5AM Venture Management, LLC	282,313	For
BlackRock	223,419	For
Octagon Capital Advisors LP	223,000	For
MPM BioImpact LLC	222,733	For
AB DISCOVERY GROWTH FUND, INC.	201,028	For

Showing the 25 largest of 132 asset managers. See all 132 in the interactive database.

2. Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Andrew Phillips

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 53,338,613WITHHELD: 244,482

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: ● Dr. Andrew Phillips”): 53,338,613 for, 244,482 withheld, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 72% for, 0.4% withheld (73% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (11,329,105 for, 0 against).

FOR 99%

FOR: 11,329,105 (98.9%)ABSTAIN: 125,441 (1.1%)

Largest asset managers voting on “Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholde” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	4,329,597	0	For
T. Rowe Price	2,278,993	0	For
Federated Hermes	1,224,322	0	For
HARBOR FUNDS	704,819	0	For
ALGER FUNDS	533,756	0	For
AllianceBernstein	339,013	0	For
AB DISCOVERY GROWTH FUND, INC.	201,028	0	For
Putnam	191,500	0	For
Columbia Threadneedle	187,720	0	For
Victory Capital	174,486	0	For
Voya	166,929	0	For
BlackRock	14,563	118,397	Abstain
Harbor Funds II	102,020	0	For
TIAA	97,175	0	For
Manager Directed Portfolios	95,704	0	For
Vanguard	90,025	0	For
Delaware/Macquarie	80,000	0	For
Equitable	75,106	0	For
Bridge Builder Trust	72,535	0	For
Goldman Sachs	71,623	0	For
Principal	65,889	0	For
Morgan Stanley	41,502	0	For
ALGER PORTFOLIOS	30,605	0	For
John Hancock	26,846	0	For
ALPS ETF Trust	25,401	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

3. Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Jorge Santos da Silva

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 53,083,965WITHHELD: 499,130

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: ● Dr. Jorge Santos da Silva”): 53,083,965 for, 499,130 withheld, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 72% for, 0.7% withheld (73% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (11,447,502 for, 0 against).

FOR 99.9%

FOR: 11,447,502 (99.9%)ABSTAIN: 7,044 (0.1%)

Largest asset managers voting on “Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholde” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset manager	For	Vote
Fidelity	4,329,597	For
T. Rowe Price	2,278,993	For
Federated Hermes	1,224,322	For
HARBOR FUNDS	704,819	For
ALGER FUNDS	533,756	For
AllianceBernstein	339,013	For
AB DISCOVERY GROWTH FUND, INC.	201,028	For
Putnam	191,500	For
Columbia Threadneedle	187,720	For
Victory Capital	174,486	For
Voya	166,929	For
BlackRock	132,960	For
Harbor Funds II	102,020	For
TIAA	97,175	For
Manager Directed Portfolios	95,704	For
Vanguard	90,025	For
Delaware/Macquarie	80,000	For
Equitable	75,106	For
Bridge Builder Trust	72,535	For
Goldman Sachs	71,623	For
Principal	65,889	For
Morgan Stanley	41,502	For
ALGER PORTFOLIOS	30,605	For
John Hancock	26,846	For
ALPS ETF Trust	25,401	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

4. Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Simon Sturge

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 52,034,156WITHHELD: 1,548,939

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: ● Simon Sturge”): 52,034,156 for, 1,548,939 withheld, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 71% for, 2% withheld (73% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (10,382,221 for, 0 against).

FOR 91%9%

FOR: 10,382,221 (90.6%)ABSTAIN: 1,072,325 (9.4%)

Largest asset managers voting on “Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholde” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	4,329,597	0	For
T. Rowe Price	2,278,993	0	For
Federated Hermes	1,224,322	0	For
HARBOR FUNDS	704,819	0	For
ALGER FUNDS	533,756	0	For
AllianceBernstein	0	339,013	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	201,028	Abstain
Putnam	191,500	0	For
Columbia Threadneedle	0	187,720	Abstain
Victory Capital	174,486	0	For
Voya	166,929	0	For
BlackRock	14,563	118,397	Abstain
Harbor Funds II	102,020	0	For
TIAA	97,175	0	For
Manager Directed Portfolios	95,704	0	For
Vanguard	90,025	0	For
Delaware/Macquarie	0	80,000	Abstain
Equitable	1,872	73,234	Abstain
Bridge Builder Trust	72,535	0	For
Goldman Sachs	71,623	0	For
Principal	0	65,889	Abstain
Morgan Stanley	41,502	0	For
ALGER PORTFOLIOS	30,605	0	For
John Hancock	26,846	0	For
ALPS ETF Trust	25,401	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. RATIFICATION, BY ORDINARY RESOLUTION, OF THE SELECTION OF BAKER TILLY US, LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 59,310,209AGAINST: 2,856

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Proposal 2: Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor”): 59,310,209 for, 2,856 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 81% for, 0.1% against (81% of the company cast a for/against vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (11,447,502 for, 0 against).

FOR 99.9%

FOR: 11,447,502 (99.9%)ABSTAIN: 7,044 (0.1%)

Largest asset managers voting on “RATIFICATION, BY ORDINARY RESOLUTION, OF THE SELECTION OF BAKER TILLY US, LLP AS THE COMPANY'S INDEPENDENT REG” at MOONLAKE IMMUNOTHERAPEUTICS, 2024-2025
Asset manager	For	Vote
Fidelity	4,329,597	For
T. Rowe Price	2,278,993	For
Federated Hermes	1,224,322	For
HARBOR FUNDS	704,819	For
ALGER FUNDS	533,756	For
AllianceBernstein	339,013	For
AB DISCOVERY GROWTH FUND, INC.	201,028	For
Putnam	191,500	For
Columbia Threadneedle	187,720	For
Victory Capital	174,486	For
Voya	166,929	For
BlackRock	132,960	For
Harbor Funds II	102,020	For
TIAA	97,175	For
Manager Directed Portfolios	95,704	For
Vanguard	90,025	For
Delaware/Macquarie	80,000	For
Equitable	75,106	For
Bridge Builder Trust	72,535	For
Goldman Sachs	71,623	For
Principal	65,889	For
Morgan Stanley	41,502	For
ALGER PORTFOLIOS	30,605	For
John Hancock	26,846	For
ALPS ETF Trust	25,401	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Largest MOONLAKE IMMUNOTHERAPEUTICS shareholders voting in 2024-2025

Ranked by the number of MOONLAKE IMMUNOTHERAPEUTICS shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 73,615,396 shares outstanding at the time of that meeting.

Top MOONLAKE IMMUNOTHERAPEUTICS shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BVF INC/IL	26.83%
2	Fidelity	13.84%
3	Cormorant Asset Management, LP	10.21%
4	T. Rowe Price	6.92%
5	Federated Hermes	3.34%
6	Citadel	1.91%
7	WESTFIELD CAPITAL MANAGEMENT CO LP	1.74%
8	AllianceBernstein	1.67%
9	Avoro Capital Advisors LLC	1.59%
10	HARBOR FUNDS	0.96%

Reported MOONLAKE IMMUNOTHERAPEUTICS ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

MOONLAKE IMMUNOTHERAPEUTICS beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Certain funds managed by BVF Partners L.P.	26.83%	DEF14A
BVF PARTNERS L P/IL	21.74%	13D
Entities affiliated with Bihua Chen	11.54%	DEF14A
FMR (Fidelity)	8.59%	13F
Deep Track Capital, LP	6.26%	13G
Dr. Kristian Reich	4.18%	DEF14A
Dr. Jorge Santos da Silva	4.18%	DEF14A
T. Rowe Price	4.04%	13F
Chen Bihua	2.71%	13G
Citadel Advisors	2.03%	13F

Percentages above are of 73,615,396 shares outstanding, as reported by MOONLAKE IMMUNOTHERAPEUTICS on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MOONLAKE IMMUNOTHERAPEUTICS’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At MOONLAKE IMMUNOTHERAPEUTICS's shareholder meeting held 2025-06-05, in the 2024-2025 proxy season, 134 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 707 separate fund positions. On the most widely held item on that ballot — Approval of, on a non-binding, advisory basis, the compensation of the Company's named… — FOR was 99.7% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MOONLAKE IMMUNOTHERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-06.

MOONLAKE IMMUNOTHERAPEUTICS proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.